SCHEMBL3320601

SCHEMBL3320601

Cc1c(C(N)=O)sc2nc(N)nc(-c3ccccc3)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.54
HTT P42858 4/20 0.52
LIMK1 P53667 4/20 0.52
ALDH1A1 P00352 4/20 0.52
MAPT P10636 3/20 0.52
KDM4E B2RXH2 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
BRAF P15056 1/20 0.52
PDE4A P27815 1/20 0.52
PDE4B Q07343 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
CDK8 P49336 1/20 0.47
CDK19 Q9BWU1 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
HSP90AB1 P08238 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27663684 0.80 MAPT (0.63) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL6110243 0.79 IKBKB (0.64) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL6441741 0.77 ALDH1A1 (0.67) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL3321340 0.77 KDM4E (0.67) IKBKBHTTALDH1A1MAPTKDM4E
SCHEMBL13750084 0.76 KMT2A (0.50) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL13109754 0.75 ALDH1A1 (0.59) HTTALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4924409 0.74 BRAF (0.70) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL4929795 0.74 BRAF (0.68) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL4907028 0.74 BRAF (0.76) IKBKBHTTLIMK1ALDH1A1MAPT
SCHEMBL6217652 0.73 LIMK1 (0.58) IKBKBHTTLIMK1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
CN-100455586-C Pyrimidothiophene compounds VERNALIS CAMBRIDGE LTD (GB) 2009-01-28 CN disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
CN-1842532-A Pyrimidothiophene compounds VERNALIS CAMBRIDGE LTD (GB) 2006-10-04 CN disclosed
EP-1675861-A1 PYRIMIDOTHIOPHENE COMPOUNDS Vernalis (Cambridge) Limited (GB) 2006-07-05 EP disclosed
WO-2005021552-A1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS (CAMBRIDGE) LTD (GB) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120767-A1 Pyrimidothiophene Compounds ALK, HSP90AA1, HSP90AB1 IKBKB 2376/4885HTT 659/4885LIMK1 3090/4885
US-20070043044-A1 Pyrimidothiophene compounds ALK, HSP90AA1, HSP90AB1 IKBKB 2113/4885HTT 446/4885LIMK1 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.